282 related articles for article (PubMed ID: 17653094)
1. Reversal of methylation silencing of Apo2L/TRAIL receptor 1 (DR4) expression overcomes resistance of SK-MEL-3 and SK-MEL-28 melanoma cells to interferons (IFNs) or Apo2L/TRAIL.
Bae SI; Cheriyath V; Jacobs BS; Reu FJ; Borden EC
Oncogene; 2008 Jan; 27(4):490-8. PubMed ID: 17653094
[TBL] [Abstract][Full Text] [Related]
2. Overcoming resistance to interferon-induced apoptosis of renal carcinoma and melanoma cells by DNA demethylation.
Reu FJ; Bae SI; Cherkassky L; Leaman DW; Lindner D; Beaulieu N; MacLeod AR; Borden EC
J Clin Oncol; 2006 Aug; 24(23):3771-9. PubMed ID: 16801630
[TBL] [Abstract][Full Text] [Related]
3. Expression of RASSF1A, an epigenetically silenced tumor suppressor, overcomes resistance to apoptosis induction by interferons.
Reu FJ; Leaman DW; Maitra RR; Bae SI; Cherkassky L; Fox MW; Rempinski DR; Beaulieu N; MacLeod AR; Borden EC
Cancer Res; 2006 Mar; 66(5):2785-93. PubMed ID: 16510600
[TBL] [Abstract][Full Text] [Related]
4. Epigenetic silencing of death receptor 4 mediates tumor necrosis factor-related apoptosis-inducing ligand resistance in gliomas.
Elias A; Siegelin MD; Steinmüller A; von Deimling A; Lass U; Korn B; Mueller W
Clin Cancer Res; 2009 Sep; 15(17):5457-65. PubMed ID: 19706813
[TBL] [Abstract][Full Text] [Related]
5. Contribution of epigenetic silencing of tumor necrosis factor-related apoptosis inducing ligand receptor 1 (DR4) to TRAIL resistance and ovarian cancer.
Horak P; Pils D; Haller G; Pribill I; Roessler M; Tomek S; Horvat R; Zeillinger R; Zielinski C; Krainer M
Mol Cancer Res; 2005 Jun; 3(6):335-43. PubMed ID: 15972852
[TBL] [Abstract][Full Text] [Related]
6. Preferential induction of apoptosis by interferon (IFN)-beta compared with IFN-alpha2: correlation with TRAIL/Apo2L induction in melanoma cell lines.
Chawla-Sarkar M; Leaman DW; Borden EC
Clin Cancer Res; 2001 Jun; 7(6):1821-31. PubMed ID: 11410525
[TBL] [Abstract][Full Text] [Related]
7. Promotion of TRAIL/Apo2L-induced apoptosis by low-dose interferon-β in human malignant melanoma cells.
Kazaana A; Sano E; Yoshimura S; Makita K; Hara H; Yoshino A; Ueda T
J Cell Physiol; 2019 Aug; 234(8):13510-13524. PubMed ID: 30613977
[TBL] [Abstract][Full Text] [Related]
8. Development of TRAIL resistance by radiation-induced hypermethylation of DR4 CpG island in recurrent laryngeal squamous cell carcinoma.
Lee JC; Lee WH; Min YJ; Cha HJ; Han MW; Chang HW; Kim SA; Choi SH; Kim SW; Kim SY
Int J Radiat Oncol Biol Phys; 2014 Apr; 88(5):1203-11. PubMed ID: 24661673
[TBL] [Abstract][Full Text] [Related]
9. Effect of DR4 promoter methylation on the TRAIL-induced apoptosis in lung squamous carcinoma cell.
Wang W; Qi X; Wu M
Oncol Rep; 2015 Oct; 34(4):2115-25. PubMed ID: 26238205
[TBL] [Abstract][Full Text] [Related]
10. Augmentation of effects of interferon-stimulated genes by reversal of epigenetic silencing: potential application to melanoma.
Borden EC
Cytokine Growth Factor Rev; 2007; 18(5-6):491-501. PubMed ID: 17689283
[TBL] [Abstract][Full Text] [Related]
11. Resistance of T-cell acute lymphoblastic leukemia to tumor necrosis factor--related apoptosis-inducing ligand-mediated apoptosis.
Akahane K; Inukai T; Zhang X; Hirose K; Kuroda I; Goi K; Honna H; Kagami K; Nakazawa S; Endo K; Kubota T; Yagita H; Koyama-Okazaki T; Sugita K
Exp Hematol; 2010 Oct; 38(10):885-95. PubMed ID: 20670671
[TBL] [Abstract][Full Text] [Related]
12. Silencing of the XAF1 gene by promoter hypermethylation in cancer cells and reactivation to TRAIL-sensitization by IFN-beta.
Micali OC; Cheung HH; Plenchette S; Hurley SL; Liston P; LaCasse EC; Korneluk RG
BMC Cancer; 2007 Mar; 7():52. PubMed ID: 17376236
[TBL] [Abstract][Full Text] [Related]
13. Resistance to TRAIL-induced apoptosis in primitive neuroectodermal brain tumor cells correlates with a loss of caspase-8 expression.
Grotzer MA; Eggert A; Zuzak TJ; Janss AJ; Marwaha S; Wiewrodt BR; Ikegaki N; Brodeur GM; Phillips PC
Oncogene; 2000 Sep; 19(40):4604-10. PubMed ID: 11030149
[TBL] [Abstract][Full Text] [Related]
14. Cardiac glycosides initiate Apo2L/TRAIL-induced apoptosis in non-small cell lung cancer cells by up-regulation of death receptors 4 and 5.
Frese S; Frese-Schaper M; Andres AC; Miescher D; Zumkehr B; Schmid RA
Cancer Res; 2006 Jun; 66(11):5867-74. PubMed ID: 16740726
[TBL] [Abstract][Full Text] [Related]
15. Increased caspase-2 activity is associated with induction of apoptosis in IFN-beta sensitive melanoma cell lines.
Kamiya T; Okabayashi T; Yokota S; Kan Y; Ogino J; Yamashita T; Fujii N; Jimbow K
J Interferon Cytokine Res; 2010 May; 30(5):349-57. PubMed ID: 20187765
[TBL] [Abstract][Full Text] [Related]
16. Membrane expression of DR4, DR5 and caspase-8 levels, but not Mcl-1, determine sensitivity of human myeloma cells to Apo2L/TRAIL.
Gómez-Benito M; Martinez-Lorenzo MJ; Anel A; Marzo I; Naval J
Exp Cell Res; 2007 Jul; 313(11):2378-88. PubMed ID: 17462628
[TBL] [Abstract][Full Text] [Related]
17. Analysis of receptors, cell surface antigens, and proteins in human melanoma cell lines resistant to human recombinant beta- or gamma-interferon.
Gomi K; Akinaga S; Oka T; Morimoto M
Cancer Res; 1986 Dec; 46(12 Pt 1):6211-6. PubMed ID: 2430691
[TBL] [Abstract][Full Text] [Related]
18. Decreased expression of KAI1/CD82 metastasis suppressor gene is associated with loss of heterozygosity in melanoma cell lines.
Kim YI; Shin MK; Lee JW; Chung JH; Lee MH
Oncol Rep; 2009 Jan; 21(1):159-64. PubMed ID: 19082457
[TBL] [Abstract][Full Text] [Related]
19. Hypermethylation of the death-associated protein kinase promoter attenuates the sensitivity to TRAIL-induced apoptosis in human non-small cell lung cancer cells.
Tang X; Wu W; Sun SY; Wistuba II; Hong WK; Mao L
Mol Cancer Res; 2004 Dec; 2(12):685-91. PubMed ID: 15634757
[TBL] [Abstract][Full Text] [Related]
20. IFN-beta pretreatment sensitizes human melanoma cells to TRAIL/Apo2 ligand-induced apoptosis.
Chawla-Sarkar M; Leaman DW; Jacobs BS; Borden EC
J Immunol; 2002 Jul; 169(2):847-55. PubMed ID: 12097388
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
